Deal terms include $2.0 billion upfront and up to $200 million milestone-based consideration, with closing anticipated in ...

DTP functions as an “affordability waterfall,” dynamically routing patients to MFN cash pricing, commercial insurance, or ...

Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...

Shareholder approval positions Garijo to steer strategy toward operational rigor, portfolio discipline, and more consistent ...

In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk ...

ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...

In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, discusses how and why ...

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene ...

In today’s Pharmaceutical Executive Daily, Sanofi formally confirms its CEO leadership following a shareholder vote, US ...

In today's Pharmaceutical Executive Daily, we cover Sun Pharma's $11.75 billion acquisition of Organon and IMG Pharma's move ...